Authors:
Sharif, NA
Xu, SX
Crider, JY
McLaughlin, M
Davis, TL
Citation: Na. Sharif et al., Levobetaxolol (Betaxon(TM)) and other beta-adrenergic antagonists: Preclinical pharmacology, IOP-lowering activity and sites of action in human eyes, J OCUL PH T, 17(4), 2001, pp. 305-317
Authors:
Hill, CE
Kelley, FA
Davis, TL
Crook, RE
Maldonado, LE
Turkson, MA
Wonnell, TL
Suthakaran, V
Zack, JS
Rochlen, AB
Kolchakian, MR
Codrington, JN
Citation: Ce. Hill et al., Predictors of outcome of dream interpretation sessions: Volunteer client characteristics, dream characteristics, and type of interpretation, DREAMING, 11(2), 2001, pp. 53-72
Citation: Pk. Keel et al., Relationship between depression and body dissatisfaction in women diagnosed with bulimia nervosa, INT J EAT D, 30(1), 2001, pp. 48-56
Citation: Tl. Davis et al., Unique expression pattern of the alpha 6 beta 4 integrin and laminin-5 in human prostate carcinoma, PROSTATE, 46(3), 2001, pp. 240-248
Authors:
Zhang, YJ
Davis, TL
Wang, XP
Deng, JH
Baillargeon, J
Yeh, IT
Jenson, HB
Gao, SJ
Citation: Yj. Zhang et al., Distinct distribution of rare US genotypes of Kaposi's sarcoma-associated herpesvirus (KSHV) in South Texas: Implications for KSHV epidemiology, J INFEC DIS, 183(1), 2001, pp. 125-129
Citation: Rd. Benson et Tl. Davis, Time-lapse seismic monitoring and dynamic reservoir characterization, central vacuum unit, Lea County, New Mexico, SPE R E ENG, 3(1), 2000, pp. 88-97
Authors:
Davis, TL
Yang, GJ
McCarrey, JR
Bartolomei, MS
Citation: Tl. Davis et al., The H19 methylation imprint is erased and re-established differentially onthe parental alleles during male germ cell development, HUM MOL GEN, 9(19), 2000, pp. 2885-2894
Authors:
Jorga, KM
Davis, TL
Kurth, MC
Saint-Hilaire, MH
LeWitt, PA
Fotteler, B
Zurcher, G
Rabbia, M
Citation: Km. Jorga et al., Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism, CLIN NEUROP, 23(2), 2000, pp. 98-105
Citation: Na. Sharif et al., Pharmacology and autoradiography of human DP prostanoid receptors using [H-3]-BWA868C, a DP receptor-selective antagonist radioligand, BR J PHARM, 131(6), 2000, pp. 1025-1038
Citation: Tl. Davis et Na. Sharif, Pharmacological characterization of [H-3]-prostaglandin E-2 binding to thecloned human EP4 prostanoid receptor, BR J PHARM, 130(8), 2000, pp. 1919-1926